Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2022

View Archived Issues

Loss of PHGDH potentiates metastatic dissemination

Kymera Therapeutics presents data on the IRAK4 degrader KT-474 in different cell subsets

Shenzhen Chipscreen Biosciences divulges PD-1/PD-L1 and/or CD80/PD-L1 interaction inhibitors

Idorsia Pharmaceuticals patents new LGALS3 inhibitors

Follicum AB and University of Bradford disclose compounds for skin and hair disorders

Boehringer Ingelheim Pharma KG identifies new EGFR mutant inhibitors

New c-Myc inhibitors presented by Suzhou Kintor Pharmaceuticals

Entrada's EEV treatments progress for Duchenne muscular dystrophy, myotonic dystrophy type 1

AKAP11 is a risk gene shared by bipolar disorder and schizophrenia

Salubris submits CTA in Europe for CTLA-4/IL-15 antibody fusion protein JK-08

FDA grants orphan drug designation to DepYmed's DPM-1001 for Wilson disease

KaliVir and Roche to collaborate on novel oncolytic vaccinia viruses

Aptamer and PinotBio extend collaboration to develop Optimer-drug conjugates

PharmaCyte studies pancreatic cancer therapy to treat malignant ascites

Anti-IL13RA1 eblasakimab reduces neuronal response to proinflammatory cytokines

Research on IL-38 mRNA expression in cancers supports Immunome's development of IMM-ONC-01

Elicio shows AMP vaccination significantly enhances TCR-T antitumor response in tumor model

Quoin enters research agreement with QUT to target VCAM-1:VL-4 interaction to treat scleroderma

Antigen-specific immunotolerance platform shows preclinical proof of concept for Parkinson's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...